|
ÁÖ½Äȸ»ç ¸Þµð½êÀÌ |
±¹³»¿µ¾÷/¼ÛÆı¸ ±Ù¹«(µ¿È¾àÇ° ÀÚȸ»ç - ÀÇ·á±â±â»ç¾÷ºÎ¹®)
¼¿ï ¼ÛÆı¸ | ´ëÇÐ(2~3³â) Á¹¾÷ |
Á¦¾à¿µ¾÷/ÀÇ·á±â¿µ¾÷ |
°æ·Â¹«°ü |
ä¿ë½Ã |
05.10 |
|
|
³ëº¸³ëµð½ºÅ©Á¦¾à(ÁÖ) |
[±Û·Î¹ú Á¦¾à»ç] Multi-Channel Engagement Manager
¼¿ï ¼ÛÆı¸ | ´ëÇÐ(4³â) Á¹¾÷ |
¸¶ÄÉÆÃ/±âȹ/±³À° |
7³â¡è |
ä¿ë½Ã |
04.29 |
|
|
³ëº¸³ëµð½ºÅ©Á¦¾à(ÁÖ) |
[±Û·Î¹ú Á¦¾à»ç] Market Access Lead, Cardiovascular and E
¼¿ï ¼ÛÆı¸ | ´ëÇÐ(4³â) Á¹¾÷ |
¿¬±¸/¿¬±¸±âȹ |
3³â¡è |
ä¿ë½Ã |
04.29 |
|
|
³ëº¸³ëµð½ºÅ©Á¦¾à(ÁÖ) |
[±Û·Î¹ú Á¦¾à»ç] Medical Advisor ä¿ë
¼¿ï ¼ÛÆı¸ | ´ëÇпø(¼®»ç) Á¹¾÷ |
¿¬±¸/¿¬±¸±âȹ |
5³â¡è |
ä¿ë½Ã |
04.29 |
|
|
³ëº¸³ëµð½ºÅ©Á¦¾à(ÁÖ) |
[±Û·Î¹ú Á¦¾à»ç] Sr. Regional Medical Advisor / Sr. Medic
¼¿ï ¼ÛÆı¸ | ´ëÇÐ(4³â) Á¹¾÷ |
¿¬±¸/¿¬±¸±âȹ |
4³â¡è |
ä¿ë½Ã |
04.30 |
|
|
´º·ÎÇÍ ÁÖ½Äȸ»ç |
ÇØ¿Ü¿µ¾÷
¼¿ï °³²±¸ | ´ëÇÐ(4³â) Á¹¾÷ |
¹«¿ª/ÇØ¿Ü¿µ¾÷/Åë¹ø¿ª |
3³â¡è |
ä¿ë½Ã |
05.13 |
|
|
Novotech |
Pharmacovigilance Associate (Snr)_Korean Speaker Only
¼¿ï °³²±¸ | ´ëÇÐ(4³â) Á¹¾÷ |
»ó¹Ý±â »ç¿ø¸ðÁý |
1³â¡è |
ä¿ë½Ã |
03.13 |
|
|
Novotech |
[Novotech] Associate Clinical Data Manager Á¤±ÔÁ÷ ä¿ë
¼¿ï °³²±¸ | ´ëÇÐ(4³â) Á¹¾÷ |
STAT/DM |
1³â¡è |
ä¿ë½Ã |
|
|
|
Novotech |
Associate Clinical Data Manager
¼¿ï °³²±¸ | ´ëÇÐ(4³â) Á¹¾÷ |
STAT/DM |
1³â¡è |
ä¿ë½Ã |
04.22 |
|
|
Novotech |
[Novotech] Business Development Manager ä¿ë
¼¿ï °³²±¸ | ´ëÇÐ(4³â) Á¹¾÷ |
»ý¸í°øÇÐ/¹ÙÀÌ¿À ¿µ¾÷ |
3³â¡è |
ä¿ë½Ã |
04.04 |
|
|
Janssen |
[Janssen] Project Manager (Local Trial Manager)
¼¿ï ¿ë»ê±¸ | ´ëÇÐ(4³â) Á¹¾÷ |
»ó¹Ý±â »ç¿ø¸ðÁý |
2³â¡è |
ä¿ë½Ã |
01.29 |
|
|
¹Ì·¡ÄÄÆÛ´Ï |
[¹Ì·¡ÄÄÆÛ´Ï/¼¿ï] ÇコÄɾî(ÀÇ·á±â±â) - ÇØ¿Ü¿µ¾÷
¼¿ï ¼ÛÆı¸ | ´ëÇÐ(4³â) ÀçÇÐ |
Á¦¾à¿µ¾÷/ÀÇ·á±â¿µ¾÷ |
2³â¡è |
ä¿ë½Ã |
02.21 |
|
|
¿¡À̽º¸ÞµðÄ®(ÁÖ) |
ÀÇ·á±â±â ¿¬±¸¿ø(±â±¸ ¼³°è) °æ·Â
¼¿ï °µ¿±¸ | ´ëÇÐ(4³â) Á¹¾÷ |
CAD |
1³â¡è |
ä¿ë½Ã |
03.27 |
|
|
¿¡À̽º¸ÞµðÄ®(ÁÖ) |
Ç°Áú°ü¸®ºÎ RAºÎ¹® ½ÅÀÔ/°æ·Â ä¿ë
¼¿ï °µ¿±¸ | ´ëÇÐ(4³â) Á¹¾÷ |
ÀÓ»ó BD/RA/QA |
°æ·Â¹«°ü |
ä¿ë½Ã |
12.13 |
|
|
¿¡À̽º¸ÞµðÄ®(ÁÖ) |
ÀÇ·á±â±â ±¹³»¿µ¾÷ ½ÅÀÔ/°æ·Â
¼¿ï °µ¿±¸ | ´ëÇÐ(4³â) Á¹¾÷ |
Á¦¾à¿µ¾÷/ÀÇ·á±â¿µ¾÷ |
°æ·Â¹«°ü |
ä¿ë½Ã |
12.11 |
|